Latest Articles
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer - Pharmacy Times
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer Pharmacy Times
Published: Oct. 21, 2025, 3:34 a.m.
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO - Citeline News & Insights
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO Citeline News & Insights
Published: Oct. 20, 2025, 10:35 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 20, 2025, 9:33 p.m.
Global Study Reports Rise in Several Cancers Among Adults of All Ages - MedPage Today
Global Study Reports Rise in Several Cancers Among Adults of All Ages MedPage Today
Published: Oct. 20, 2025, 9:27 p.m.
Ibuprofen: How An Everyday Drug Might Offer Protection Against Cancer - Study Finds
Ibuprofen: How An Everyday Drug Might Offer Protection Against Cancer Study Finds
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer - Femtech Insider
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer Femtech Insider
Published: Oct. 20, 2025, 2:27 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Yahoo
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Yahoo
Published: Oct. 20, 2025, 2:07 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena
Published: Oct. 20, 2025, 1:12 p.m.
Tondiamo Yellow Ribbon Lapel Pins Childhood Cancer Awareness Endometriosis Bone Cancer Brooch Pins for Public Charity Fundraiser Events Supplies Gifts - The San Joaquin Valley Sun
Tondiamo Yellow Ribbon Lapel Pins Childhood Cancer Awareness Endometriosis Bone Cancer Brooch Pins for Public Charity Fundraiser Events Supplies Gifts The San Joaquin Valley Sun
Published: Oct. 20, 2025, 12:36 p.m.
Link copied to clipboard!